Biomarkers for dementia in Latin American countries: Gaps and opportunities

Nenhuma Miniatura disponível
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
PARRA, Mario A.
ORELLANA, Paulina
LEON, Tomas
VICTORIA, Cabello G.
HENRIQUEZ, Fernando
GOMEZ, Rodrigo
AVALOS, Constanza
DAMIAN, Andres
SLACHEVSKY, Andrea
IBANEZ, Agustin
Citação
ALZHEIMERS & DEMENTIA, v.19, n.2, p.721-735, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.
Palavras-chave
Referências
  1. Alawode DOT, 2021, J INTERN MED, V290, P583, DOI 10.1111/joim.13332
  2. Parra MA, 2021, ALZHEIMERS DEMENT, V17, P295, DOI 10.1002/alz.12202
  3. Allegri RF, 2021, NEUROLOGIA, V36, P201, DOI 10.1016/j.nrl.2017.12.011
  4. Allegri RF, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12026
  5. Alzheimer's Disease International, 2015, WORLD ALZHEIMER REPO, DOI 10.1111/J.0963-7214.2004.00293.X
  6. Aschenbrenner AJ, 2018, NEUROLOGY, V91, pE859, DOI 10.1212/WNL.0000000000006075
  7. Ashton Nicholas J, 2015, Alzheimers Dement (Amst), V1, P48, DOI 10.1016/j.dadm.2014.11.005
  8. Baez S, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00253
  9. Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016
  10. Bachli MB, 2020, NEUROIMAGE, V208, DOI 10.1016/j.neuroimage.2019.116456
  11. Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1
  12. Bobinski M, 2000, NEUROSCIENCE, V95, P721
  13. Buch KBN, 1999, NEUROSCI LETT, V277, P21
  14. Cecchini MA, 2021, BRAIN COGNITION, V152, DOI [10.1016/j.bc.2021.105749, 10.1016/j.bandc.2021.105749]
  15. Coutinho AM, 2020, EUR J NUCL MED MOL I, V47, P2666, DOI 10.1007/s00259-020-04714-0
  16. Cruts M, 1996, HUM MOL GENET, V5, P1449, DOI 10.1093/hmg/5.Supplement_1.1449
  17. Cummings J, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0529-5
  18. Damian A, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.630958
  19. de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198
  20. de Souza GS, 2022, MOL IMAGING BIOL, V24, P394, DOI 10.1007/s11307-021-01660-7
  21. DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011
  22. Di Tella S, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.735508
  23. Drzezga A, 2003, EUR J NUCL MED MOL I, V30, P1104, DOI 10.1007/s00259-003-1194-1
  24. Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3
  25. Duran-Aniotz C, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.663407
  26. El Kadmiri N, 2018, NEUROSCIENCE, V370, P181, DOI 10.1016/j.neuroscience.2017.07.017
  27. Reyes-Pablo AE, 2020, J ALZHEIMERS DIS, V76, P853, DOI 10.3233/JAD-191015
  28. Faria DD, 2019, BRAZ J PSYCHIAT, V41, P101, DOI 10.1590/1516-4446-2017-0002
  29. Goate A, 2006, J ALZHEIMERS DIS, V9, P341
  30. Gullett JM, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.758298
  31. Hampel H, 2004, ARCH GEN PSYCHIAT, V61, P95, DOI 10.1001/archpsyc.61.1.95
  32. Hampel H, 2008, ALZHEIMERS DEMENT, V4, P38, DOI 10.1016/j.jalz.2007.08.006
  33. Hampel H, 2018, NAT REV NEUROL, V14, P639, DOI 10.1038/s41582-018-0079-7
  34. Hansen EO, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.716686
  35. Ibanez A, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.631722
  36. Ibanez A, 2021, J ALZHEIMERS DIS, V82, pS379, DOI 10.3233/JAD-201384
  37. Irizarry Michael C, 2004, NeuroRx, V1, P226
  38. Jack CR, 2016, NEUROLOGY, V87, P539, DOI 10.1212/WNL.0000000000002923
  39. Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018
  40. Khan TK, 2015, J ALZHEIMERS DIS, V44, P729, DOI 10.3233/JAD-142262
  41. Koychev I, 2017, J ALZHEIMERS DIS, V60, P283, DOI 10.3233/JAD-170129
  42. LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622
  43. Lista S, 2013, PROG NEUROBIOL, V101, P1, DOI 10.1016/j.pneurobio.2012.06.007
  44. Lourenco MV, 2021, J ALZHEIMERS DIS, V82, P1067, DOI 10.3233/JAD-210147
  45. Lourenco MV, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12034
  46. Madeira C, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.52
  47. Madeira C, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00561
  48. Magaki S, 2014, J AM GERIATR SOC, V62, P1722, DOI 10.1111/jgs.12977
  49. Manes F, 2016, LANCET NEUROL, V15, P29, DOI 10.1016/S1474-4422(15)00360-9
  50. Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064
  51. MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
  52. Menon MC, 2017, J AM SOC NEPHROL, V28, P735, DOI 10.1681/ASN.2016080858
  53. Nitrini R, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010362
  54. Nitrini R, 2009, INT PSYCHOGERIATR, V21, P622, DOI 10.1017/S1041610209009430
  55. O'Bryant SE, 2017, ALZHEIMERS DEMENT, V13, P45, DOI 10.1016/j.jalz.2016.09.014
  56. Ogonowski N, 2022, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.807764
  57. Ossenkoppele R, 2019, NEUROLOGY, V92, pE601, DOI 10.1212/WNL.0000000000006875
  58. Parra MA, 2018, NEUROLOGY, V90, P222, DOI 10.1212/WNL.0000000000004897
  59. Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617
  60. Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007
  61. Reiman EM, 2012, LANCET NEUROL, V11, P1048, DOI 10.1016/S1474-4422(12)70228-4
  62. SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467
  63. Sexton C, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.633777
  64. Shiino A, 2021, ALZH DEMENT-DADM, V13, DOI 10.1002/dad2.12246
  65. Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120
  66. Slachevsky A, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01866-4
  67. Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
  68. Teunissen CE, 2022, LANCET NEUROL, V21, P66, DOI 10.1016/S1474-4422(21)00361-6
  69. Teunissen CE, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0359-x
  70. Thambisetty M, 2010, BIOMARK MED, V4, P65, DOI 10.2217/BMM.09.84
  71. Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2
  72. Tutor CA., 2002, World J Nucl Med, V1, P219
  73. van der Flier WM, 2005, J NEUROL NEUROSUR PS, V76, pV2, DOI 10.1136/jnnp.2005.082867
  74. Wojsiat J, 2017, BIOMARK MED, V11, P917, DOI 10.2217/bmm-2017-0041
  75. Wolters FJ, 2020, NEUROLOGY, V95, pE519, DOI 10.1212/WNL.0000000000010022
  76. World Bank, 2020, List of economies
  77. Zarow C, 2005, ANN NEUROL, V57, P896, DOI 10.1002/ana.20503
  78. Zetterberg H., 2022, ACTA NEUROL SCAND, V146, P51, DOI [DOI 10.1111/ANE.13628, 10.1111/ane.13628]
  79. Zetterberg H, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00430-x
  80. Zetterberg H, 2021, MOL PSYCHIATR, V26, P296, DOI 10.1038/s41380-020-0721-9
  81. Zhou Y, 2021, ACS CHEM NEUROSCI, V12, P4209, DOI 10.1021/acschemneuro.1c00472